GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoveren Scientific Inc (OTCPK:IVRN) » Definitions » Current Ratio

Innoveren Scientific (Innoveren Scientific) Current Ratio : 0.08 (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Innoveren Scientific Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Innoveren Scientific's current ratio for the quarter that ended in Sep. 2023 was 0.08.

Innoveren Scientific has a current ratio of 0.08. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Innoveren Scientific has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Innoveren Scientific's Current Ratio or its related term are showing as below:

IVRN' s Current Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.68   Max: 39.53
Current: 0.08

During the past 10 years, Innoveren Scientific's highest Current Ratio was 39.53. The lowest was 0.01. And the median was 0.68.

IVRN's Current Ratio is ranked worse than
96.97% of 1553 companies
in the Biotechnology industry
Industry Median: 3.79 vs IVRN: 0.08

Innoveren Scientific Current Ratio Historical Data

The historical data trend for Innoveren Scientific's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoveren Scientific Current Ratio Chart

Innoveren Scientific Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.39 0.61 0.04 0.01

Innoveren Scientific Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.01 0.03 0.02 0.08

Competitive Comparison of Innoveren Scientific's Current Ratio

For the Biotechnology subindustry, Innoveren Scientific's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoveren Scientific's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoveren Scientific's Current Ratio distribution charts can be found below:

* The bar in red indicates where Innoveren Scientific's Current Ratio falls into.



Innoveren Scientific Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Innoveren Scientific's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=0.084/7.477
=0.01

Innoveren Scientific's Current Ratio for the quarter that ended in Sep. 2023 is calculated as

Current Ratio (Q: Sep. 2023 )=Total Current Assets (Q: Sep. 2023 )/Total Current Liabilities (Q: Sep. 2023 )
=0.749/9.661
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innoveren Scientific  (OTCPK:IVRN) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Innoveren Scientific Current Ratio Related Terms

Thank you for viewing the detailed overview of Innoveren Scientific's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoveren Scientific (Innoveren Scientific) Business Description

Traded in Other Exchanges
N/A
Address
2202 N West Shore Boulevard, Suite 200, Tampa, FL, USA, 33607
Innoveren Scientific Inc Formerly H-CYTE Inc is a hybrid biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. It has two divisions: the Healthcare Medical Biosciences Division (which includes the Infusion Vertical and the Biologics Vertical) and the DenerveX medical device division.
Executives
Fwhc Holdings, Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Hoa Capital Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Farrior J Rex Iii 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Fwhc Bridge Friends, Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Raymond Monteleone director 201 E KENNEDY BLVD, STE 700, TAMPA FL 33602
Jeremy Daniel officer: Chief Financial Officer 201 E KENNEDY AVE, STE 700, TAMPA FL 33602
Robert Smith Greif officer: President and C.E.O. 19 MAY STREET, NEEDHAM MA 02492
Cfrs Investments, Llc 10 percent owner 2903 W VILLA ROSA PARK, TAMPA FL 33611
Frederick J Lynch 10 percent owner C/O MASONITE INTERNATIONAL CORPORATION, 201 NORTH FRANKLIN ST., SUITE 300, TAMPA FL 33602
Fwhc Bridge, Llc 10 percent owner 334 EAST LAKE ROAD, SUITE 176, PALM HARBOT FL 34685
Todd R Wagner 10 percent owner 3385 OLD KEYSTONE ROAD, TARPON SPRINGS FL 34688
Michael Yurkowsky director 2380 OLD MILTON PARKWAY, ALPHARETTA GA 30009
William E Horne director, officer: Chief Executive Officer 201 EAST KENNEDY BLVD, SUITE 700, TAMPA FL 33602
Jon Mogford director 714 PLUM HOLLOW DRIVE, COLLEGE STATION TX 77845
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615

Innoveren Scientific (Innoveren Scientific) Headlines